Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intracranial Tumor Clear all
Active, not recruiting Not applicable Interventional

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

NCT01892397
View directory record Official record
Conditions
Brain Cancer
Interventions
Optune (NovoTTF-100A)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors

NCT03076255
View directory record Official record
Conditions
Brain and Nervous System, Intracranial Neoplasm, Head and Neck Cancer
Interventions
Computed Tomography, Medical Device, Cone-Beam Computed Tomography
Procedure · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 12, 2026, 2:53 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

Influence of MMP on Brain AVM Hemorrhage

NCT00783523
View directory record Official record
Conditions
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions
Doxycycline or Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 12, 2026, 2:53 AM EDT
Completed No phase listed Observational

Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy

NCT00214175
View directory record Official record
Conditions
Glioma, Brain Neoplasms
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions

NCT04343157
View directory record Official record
Conditions
Brain Metastases, Adult, Neurocognitive Function, Cancer, Meningioma of Brain, Arteriovenous Malformations, Cerebral
Interventions
Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
Radiation
Lead sponsor
Jona Hattangadi-Gluth
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

NCT00479765
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Neoplasms
Interventions
OncoGel (ReGel/Paclitaxel)
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014
View directory record Official record
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
783
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NCT03180268
View directory record Official record
Conditions
Grade 2 Meningioma, Intracranial Meningioma
Interventions
Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
198
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894
View directory record Official record
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

NCT07383649
View directory record Official record
Conditions
Brain Cancer Metastatic, CMV Viremia
Interventions
Valganciclovir
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 12, 2026, 2:53 AM EDT
Not yet recruiting No phase listed Observational

Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury

NCT07772323
View directory record Official record
Conditions
Acute Brain Injury, Traumatic Brain Injury, Intracranial Hemorrhage, Hydrocephalus, Stroke, Brain Neoplasm, Hypoxia-Ischemia, Brain
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

NCT00021229
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate, local irradiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional

PET Imaging of Intracranial Cancers With 18F-FSPG

NCT02370563
View directory record Official record
Conditions
Brain Cancer
Interventions
18F-FSPG
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

NCT00973739
View directory record Official record
Conditions
Neurofibromatosis 2, Vestibular Schwannoma
Interventions
Lapatinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
4 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting No phase listed Observational

A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers

NCT07467109
View directory record Official record
Conditions
Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
Interventions
blood sampling
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed No phase listed Observational

HyperArc Registry Study

NCT05270707
View directory record Official record
Conditions
Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
Interventions
Stereotactic radiosurgery
Radiation
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

NCT07150806
View directory record Official record
Conditions
Recurrent Meningioma
Interventions
Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography, Echocardiography Test, Gallium Ga 68-DOTATATE, L-lysine/L-arginine-containing Amino Acid, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Somatostatin Receptor Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
Joshua Palmer
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device

NCT05096286
View directory record Official record
Conditions
Intracranial Metastatic Disease From Any Solid Malignancy
Interventions
Ethos Therapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

NCT01884740
View directory record Official record
Conditions
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma, Pilomyxoid Astrocytoma, Mixed Oligodendroglioma-Astrocytoma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
SIACI of Erbitux and Bevacizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 12, 2026, 2:53 AM EDT
Active, not recruiting Phase 1 Interventional

T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

NCT02442297
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Refractory
Interventions
HER2-specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 12, 2026, 2:53 AM EDT